Community-Acquired Pneumonia

April 10th 2023

Can anakinra reduce inflammation and the need for mechanical ventilation in patients with severe COVID-19 pneumonia?

April 7th 2023

The pneumonia drug Atovaquone oral suspension, USP 750mg/5mL, has been voluntarily recalled due to potential Bacillus cereus contamination.

March 25th 2023

This week's hottest topics included the risks of proton pump inhibitors, rare tickborne disease, HIV vaccination, COVID-19 immunity from a common cold, and hydrocortisone for pneumonia.

March 21st 2023

After 28 days, hydrocortisone reduced the risk of mortality by 5.7% in severe community-acquired pneumonia patients.